# The crosstalk between nerves and immunity: chronic stress as a driver of tumor progression

## TL;DR

Chronic stress worsens cancer by weakening the immune system and can be countered with new strategies targeting stress signaling.

## Contribution

This paper proposes a tiered model to screen and intervene against stress-driven cancer progression using biostress biomarkers.

## Key findings

- Chronic stress disrupts anti-tumor immunity through HPA axis and sympathetic nervous system activation.
- Stress hormones promote immune evasion and metastasis by suppressing cytotoxic lymphocytes and enhancing immunosuppressive cells.
- Targeting stress signaling offers potential to improve cancer therapy outcomes and counteract multidrug resistance.

## Abstract

Chronic stress, a sustained psychophysiological state, promotes tumor progression primarily by disrupting anti-tumor immunity. Through persistent activation of the HPA axis and sympathetic nervous system, stress hormones such as glucocorticoids and catecholamines reshape the tumor microenvironment and systemically impair immune surveillance. This leads to suppressed activity of cytotoxic lymphocytes, expansion of immunosuppressive cells, and ultimately, enhanced immune evasion and metastasis. Furthermore, these pathways undermine the efficacy of conventional and emerging therapies by fostering multidrug resistance. This review highlights these mechanisms and discusses the promise of targeting stress signaling, through both pharmacological and behavioral interventions, as a strategy to improve cancer outcomes. To address the current lack of clinical guidelines for counteracting the cancer progression mediated by chronic stress, this review propose a tiered screening and intervention model based on easily accessible biostress biomarkers. This hypothesis aims to bridge the gap between basic mechanism research and clinical application, providing a theoretical foundation directional guidance for future research.